SEP 2 0 2002



PTO/SB/21 (08-00)

1641

ype a plus son (+) inside this box —>

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

OF TRADE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

			Application Number	09/841,836			
TRANSMITTAL FORM (to be used for all correspondence after initial filing)			Filing Date	April 25, 2001	BECH		
			First Named Inventor	ROBERTS et al.	RECE		
			Group Art Unit	1641	SEP 2 5		
			Examiner Name	Unassigned	TECH CENTER		
Total Number of Page	s in This Submission	8+refS	Attorney Docket Numbe	r GA0229US	- ILOH GENIEN		
		ENCLO	OSURES (check all that apply	y)			
Fee Transmittal I	=orm(dup.)		ment Papers Application)	After Allowance C	After Allowance Communication to Group		
Fee Attached	i	☐ Drawin	g(s)		Appeal Communication to Board of Appeals and Interferences		
Amendment / Re	sponse	Licensi	ng-related Papers		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)		
After Final		Petition		Proprietary Inform	Proprietary Information		
Affidavits/dec	claration(s)		n to Convert to a onal Application	Status Letter			
Extension of Tim	e Request		of Attorney, Revocation e of Correspondence Addres		Other Enclosure(s) (please identify below):		
		☐ Termin	al Disclaimer		49 (3 sheets); copy		
Express Abando	nment Request	Reques	st for Refund	and Return P	cited references; ostcard		
☐ CI			imber of CD(s)				
Certified Copy of Priority Document(s)		Rema	rks				
Response to Missing Parts/ Incomplète Application							
Response to Missing Parts under 37 CFR 1.52 or 1.53							
	SIGNA	TURE OF	APPLICANT, ATTORNEY	, OR AGENT			
	Elizabeth Lassen						
Firm or	Genzyme Corpora 15 Pleasant Street						
Individual name	P.O. Box 9322				~		
Framingham, Massachusetts 01			<i>v</i>				
Signature Clifaluth Ad Date Sept. 17, 2002			ass				
Date	Sept. 1	7, 2000	2				
		CEI	RTIFICATE OF MAILING				
I hereby certify that the	nis correspondence i	s being depo	sited with the United States F	Postal Service as first class	mail in an envelope		
addressed to: Assist	ant Commissioner fo	or Patents, W	ashington, D.C. 20231 on thi	s date: September 17, 2	2002		
Typed or printed name TARYN ANTALEK			. 1				
Signature	MOULA	/	1100/	Date 4-/	7-02-		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act 95, no persons are required to respond to a collection of infor

FEE TO ANOMITTAL	Complete if Known						
OLP FEE TRANSMITTAL	Application Number	09/841,836	RECEIVED				
o for FY 2002	Filing Date	April 25, 2001	TILOLIVED				
SEP 2 0 2002	First Named Inventor	ROBERTS, Bruce L.	SEP 2 5 2002				
SEP 2 2 ZUVL stent fees are subject to annual revision.	Examiner Name	Unassigned					
3	Group / Art Unit	1641	TECH CENTER 18 00/290				
PARE MOUNT OF PAYMENT (\$) 180	Attornov Docket No.	GA0229US					

				1 377						L		
METHOD OF PAYMENT (check all that apply)					FEE CALCULATION (continued)							
☐ Check ☐ Credit card ☐ Money ☐ Other ☐ None					3. ADD	DITIONAL Large Entity	FEES	Small Entity				
Order ☑ Deposit Account:					Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid		
Depo	osit						105	130	205	65	Surcharge - late filing fee or oath	•
Account 07-1074 Number						127	50	227	25	Surcharge - late provisional filing fee or cover sheet.		
	_ :=	_					139	130	139	130	Non-English specification	
Deposit Account GENZYME CORPORATION					147	2,520	147	2,520	For filing a request for reexamination			
Name						112	920*	112	920*	Requesting publication of SIR prior to Examiner action		
The Commissioner is authorized to: (check all that apply) ☑ Charge fee(s) indicated below ☑ Credit any overpayments					Ì	113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action		
 ☑ Charge any additional fee(s) during the pendency of this application ☐ Charge fee(s) indicated below, except for the filling fee 						115	110	215	55	Extension for reply within first month		
to the above-identified deposit account.						116	400	216	200	Extension for reply within second month		
FEE CALCULATION						117	920	217	460	Extension for reply within third month		
1. E Large	BASIC F. Entity	LING FE	EE Entity				118	1,440	218	720	Extension for reply within fourth month	
Fee	Fee	Fee	Fee	Fee Description			128	1,960	228	980	Extension for reply within fifth month	
Code	(\$)	Code	(\$)		Fee Paid	٦ ا	119	320	219	160	Notice of Appeal	
101	740	201	370	Utility filing fee		4 1	120	320	220	160	Filing a brief in support of an appeal	
106	330	206	165	Design filing fee		4	121	280	221	140	Request for oral hearing	
107 108	510 740	207 208	255 370	Plant filing fee Reissue filing fee			138	1,510	138	1,510	Petition to institute a public use proceeding	
114	160	214	80	Provisional filling fee			140	110	240	5 5	Petition to revive - unavoidable	
		_				_	141	1,280	241	640	Petition to revive - unintentional	
		S	UBTOTA	L (1)	(\$) 0	J	142	1,280	242	640	Utility issue fee (or reissue)	
2. EXTF	A CLAI	M FEES	;				143	460	243	230	Design issue fee	
				Extra Fee from	Fee		144	620	244	310	Plant issue fee	
	_			Claims below	Paid	- 1	122	130	122	130	Petitions to the Commissioner	
Total Clain	=	ᆗ`	=	0 X 18] = [0	-	123	50	123	50	Processing fee under 37 CFR 1.17 (q)	
Independen Claims	ıt		** =	0 X 84	= 0		126	180	126	180	Submission of Information Disclosure Stmt	180.00
Multiple Dependent				x	= 0]	581 .	40	581	40	Recording each patent assignment per property (times number of properties)	
Large Fee	Fee	/ Small Fee	Fee	y Fee Description			146	740	246	370	Filing a submission after final rejection (37 CFR § 1.129(a))	
Code 103	(\$) 18	Code 203	(\$) 9	Claims in excess of 20			149	740	249	370	For each additional invention to be examined (37 CFR § 1.129(b))	
102	84	202	42	Independent claims in			179	740	279	370	Request for Continued Examination (RCE)	
104	280	204	140	Multiple dependent cla		- 1					•	<u> </u>
109	84	209	42	original patent			169	900	169	900	Request for expedited examination of a design application	
110 18 210 9 ** Reissue claims in excess of 20 and over original patent					ď							
SUBTOTAL (2) (\$) 0					Other fe	e (specify	y)					
**or number previously paid, if greater; For Reissues, see above				*Reduc	ed by Ba	sic Filing	Fee Pa	aid SUBTOTAL (3) (\$) 180				
e												

SUBMITTED BY				Con	nplete (if applicable)
Name (Print/Type)	Elizabell Lassen	Registration No/ Attorney/Agent)	31,845	ТеГернопе	508-270-2553
Signature	Elijalut	G Jask		Date 9/17/	62

I THE UNITED STATES PATENT AND TRADEMARK OFFICE

RFCFIVE

pplication for:

SEP 2 5 2002

Roberts et al.

Examiner: Unassigned

TECH CENTER 1600/2900

Serial No.: 09/841,836

Group Art Unit: 1641

Filing Date: April 25, 2001

PREPARATION AND USE OF PARTICULATES COMPOSED OF For:

ADENOVIRUS PARTICLES

Commissioner for Patents Washington, D.C. 20231

Certificate of First-Class Mailing (37 C.F.R. § 1.8(a))

I hereby certify that this paper and all enclosures are being deposited with the United States Postal Service as first class mail on the date indicated below in an envelope addressed to Commissioner for Patents, Washington, D.C., 20231

Name of Person Certifying:

Printed Name: Taryn Antalek

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached Form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application.

I. Timing of the Information Disclosure Statement:

This Information Disclosure Statement is filed:

_	Affahin ahann annatha afan aha filina data af aha annalination annitalin ataun
	· · · · · · · · · · · · · · · · · · ·

With the new patent application submitted herewith (37 C.F.R. § 1.97(a)).

- Within three months after the filing date of the application or within three months after the date of entry of the national stage of a PCT application as set forth in 37 C.F.R. § 1.491.
- П Before the mailing date of a first Office Action on the merits. In the event, however, that an Office Action has crossed in the mail with this Information Disclosure Statement, the Commissioner is hereby authorized to charge Deposit Account No. 07-1074 for any fees required pursuant to 37 C.F.R. § § 1.17(p) or 1.17(i)(1).

09/23/2002 EHAILE1 00000013 071074 09841836

This Information Disclosure Statement is filed:

|X|After the first Office Action and more than three months after the application's filing date; or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever comes first, and the Commissioner is hereby authorized to charge Deposit Account No. 07-1074 for the fee (\$180.00) set forth in 37 C.F.R. § 1.17(p) and any additional required fees. This Information Disclosure Statement is filed: After the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by the fee (\$180.00) set forth in 37 C.F.R. § 1.17(i)(1) and a certification as specified in 37 C.F.R. § 1.97(e), as checked below. This document is to be considered as a petition requesting consideration of the Information Disclosure Statement. The undersigned certifies that: Each item of information contained in the Information Disclosure Statement was first cited in any communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement. No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56 more than three months prior to the filing of this Information Disclosure Statement. II. Copies of the Cited Items: X Copies of all of the items listed on the attached Form PTO-1449 are enclosed. П Copies of only the following items listed on the attached Form PTO-1449 are enclosed: . Copies of those items which are marked with an asterisk (*) in the attached Form PTO-1449 are not supplied because they were previously cited by or submitted to the Patent Office in a prior Application No.

filed and relied upon in this application for an earlier filing

date under 35 U.S.C. § 120. See 37 C.F.R. § 1.98(d).

Copies of those items which are marked with an asterisk (**) in the attached Form PTO-1449 were cited in a foreign examination report in a related case. A copy of the search report and the cited references not already of record in this application are attached hereto.

III. Concise Explanation of Relevance:

Citation of the above documents shall not be construed as:

- 1. an admission that the documents are necessarily prior art with respect to the instant invention;
- 2. a representation that a search has been made, other than as described above; or
- 3. an admission that the information cited herein is, or is considered to be, material to patentability as defined in § 1.56(b).

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO 1449 with initials or other appropriate marks.

The Commissioner is hereby authorized to charge Deposit Account No. **07-1074** for any additional fees required in connection with the filing of this Information Disclosure Statement.

Respectfully submitted,

Data

E/izabeth Lassen

Registration No. 31,845

Genzyme Corporation 15 Pleasant Street Connector P.O. Box 9322

Framingham, Massachusetts 01701-9322

Telephone: (508) 270-2553 Facsimile: (508) 872-5415